Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Brain & mental health · 2026

Juvmo (tavapadon)

The FDA approved Juvmo (tavapadon) on September 25, 2026 to treat Parkinson’s disease in adults.
Brand name
Juvmo
Generic name
tavapadon
FDA approval date
September 25, 2026
Approved use (FDA wording)
To treat Parkinson’s disease in adults
Category on this site
Brain & mental health

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.